End of FDA “grace period” impacted perinatal cell therapy biotechs

A knot in a human umbilical cord. Relatively new FDA policies have impacted perinatal cell therapy biotech companies selling umbilical cord, amniotic, and placental products, which are now generally considered drug products requiring premarket approval. Creative Commons image: Scott Granneman.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.